IFNGR1 and hepatocellular carcinoma: After their inoculation into immunocompetent C57BL/6 mice, wild-type tumors were responsive to sorafenib treatment, whereas IFNGR1-deficient tumors failed to respond (Fig. 1e), suggesting that the integrity of IFNγ signaling in HCC cells is required for TKI response in vivo.